3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
16
Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Stomach Neoplasms
1
Prostate Adenocarcinoma
1
Pancreatic Adenocarcinoma
1
Osteosarcoma
1
Oligodendroglioma
1
Neuroblastoma
1
Metastatic Castration-sensitive Prostate Cancer
1
Mesothelioma
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Paclitaxel
19
pembrolizumab
16
Carboplatin
12
Bevacizumab
7
lenvatinib
6
rucaparib
5
Nivolumab
5
Megestrol Acetate
5
Radiation
4
Indocyanine Green
4
Gemcitabine
4
Cisplatin
4
tisotumab vedotin
3
temsirolimus
3
Sirolimus
3
Sentinel Lymph Node Biopsy
3
Magnetic Resonance Spectroscopy
3
Doxorubicin
3
olaparib
2
ixabepilone
2
iso-sulfan blue
2
irosustat
2
epacadostat
2
durvalumab
2
copanlisib
2
Trastuzumab
2
Taxes
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Metformin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Endometrial Neoplasms
×
niraparib
×
Clear all
NCT05169437
2025-10-29
PAVO
Tempus AI
Phase 2
Terminated
22 enrolled
17 charts